SuperworthSeaStar Medical ICU
- Market cap
- $10.6M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 6.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $1.7M
- +124% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
SeaStar Medical trades at 6.2× sales. Revenue was $1.7M over the last twelve months, up 124% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $68K | $67K | $293K | $338K | $183K+169% | $420K+527% | $495K+69% | $615K+82% | |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $27K | $14K | $12K | $46K | $54K+100% |
| Gross profit | n/a | n/a | $0 | $0 | $68K | $67K | $293K | $311K | $169K+149% | $408K+509% | $449K+53% | $561K+80% |
| R&D | $1.1M+50% | $1.2M+42% | $1.7M−2% | $2.3M+18% | $2.3M+115% | $2.7M+133% | $2.4M+43% | $1M−56% | $1.9M−21% | $2.2M−20% | $2.3M−4% | $2.5M+143% |
| SG&A | $1.9M+78% | $1.8M−63% | $2.3M−21% | $2.3M+32% | $2.2M+18% | $2.1M+19% | $1.7M−25% | $1M−56% | $1.9M−13% | $1.2M−42% | $1.7M+1% | $1.8M+78% |
| −$2.9M+66% | −$2.9M−62% | −$4M−14% | −$4.7M+25% | −$4.5M+52% | −$4.8M+62% | −$3.8M−3% | −$1.8M−62% | −$3.6M−20% | −$3M−37% | −$3.6M−6% | −$3.8M+116% | |
| Interest expense | $224K+82% | $199K+35% | $143K−67% | $82K−64% | $272K+21% | −$253K | $11K−92% | $9K−89% | $0 | $13K | $6K−46% | $8K−11% |
| Pre-tax income | −$7.2M+282% | −$9.5M+13% | −$12.7M+79% | −$3.2M+32% | −$4.5M−38% | −$4.4M−53% | −$3.8M−70% | −$2M−38% | −$3.5M−23% | −$2.9M−34% | −$3.5M−7% | −$3.7M+86% |
| $0 | −$5K | $0 | $3K−40% | $0 | $0 | $3K | $0 | $0 | $0 | $3K+0% | $0 | |
| Net income | −$7.2M+282% | −$9.5M+13% | −$12.7M+79% | −$3.2M+32% | −$4.5M−38% | −$4.4M−53% | −$3.8M−70% | −$2M−38% | −$3.5M−23% | −$2.9M−34% | −$3.5M−7% | −$3.7M+86% |
| −$90.20+39% | −$61.50−68% | −$47.30−65% | −$10.30−75% | −$11.00−88% | −$8.98−85% | −$4.40−91% | −$1.80−83% | n/a | n/a | n/a | n/a | |
| 80.2K+177% | 153.7K+246% | 268.4K+415% | 315.5K+428% | 408.7K+410% | 492K+220% | 861.8K+221% | 1.1M+259% | n/a | n/a | n/a | n/a |
EPS, diluted: 4 periods, Q4 FY21 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY22 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest SeaStar Medical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ICUSeaStar Medical | $10.6M | n/m | 18.9× | 6.2× | +124% | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% |
More on SeaStar Medical
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .